Literature DB >> 22670178

Expression of c-Myc and Fas correlates with perineural invasion of pancreatic cancer.

Chengzhi He1, Hua Jiang, Shasha Geng, Haihui Sheng, Xiaoying Shen, Xiaoyan Zhang, Shizhang Zhu, Ximei Chen, Changqing Yang, HengJun Gao.   

Abstract

Lymph node metastasis (LNM) and perineural invasion (PNI) are regarded as two important prognostic factors in pancreatic cancer. The aim of this study was to identify the LNM-associated and PNI-associated markers in pancreatic cancer. We have constructed a formalin-fixed paraffin embedded pancreatic tissue microarrays containing 324 cylindrical tissue cores of human pancreatic cancer and its paracancerous nonmalignant pancreatic specimens (NMPs) from 162 patients. Among those patients, there were 83 of 162 with PNI, and 65 of 162 with LNM. The protein products of 2 genes encompassing a variety of functional classes, such as oncogenes (c-Myc), apoptosis (Fas), were analyzed by immunohistochemistry on the tissue microarray. There was marked increase in cancer tissues cytoplasmic c-Myc expression level in pancreatic cancer compared with the NMPs (P < 0.0001). Additionally, the expression level of c-Myc was also significant increase in pancreatic cancer with PNI compared with cancer without PNI (P < 0.01). In contrast, cytoplasmic Fas, low expressed in pancreatic cancer (P < 0.0001) was negatively correlated with PNI (P < 0.05). Logistic regression analysis showed that the c-Myc expression in the cancer tissues cytoplasm acted as a potential and independently predictive factor for PNI. However, there were no significant association between the expression of these two genes and LNM (P > 0.05). This study for the first time described expression levels of c-Myc and Fas played an important role in PNI of pancreatic cancer. Combined detection can be used as predictive factors, especially c-Myc.

Entities:  

Keywords:  Fas; Pancreatic cancer; c-Myc; perineural invasion; tissue microarrays

Mesh:

Substances:

Year:  2012        PMID: 22670178      PMCID: PMC3365821     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  33 in total

1.  Establishment of perineural invasion models and analysis of gene expression revealed an invariant chain (CD74) as a possible molecule involved in perineural invasion in pancreatic cancer.

Authors:  Norimasa Koide; Taketo Yamada; Rie Shibata; Taisuke Mori; Mariko Fukuma; Ken Yamazaki; Koichi Aiura; Motohide Shimazu; Setsuo Hirohashi; Yuji Nimura; Michiie Sakamoto
Journal:  Clin Cancer Res       Date:  2006-04-15       Impact factor: 12.531

2.  Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway.

Authors:  Malte Buchholz; Alexandra Schatz; Martin Wagner; Patrick Michl; Thomas Linhart; Guido Adler; Thomas M Gress; Volker Ellenrieder
Journal:  EMBO J       Date:  2006-07-27       Impact factor: 11.598

3.  Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis.

Authors:  Yu-Jun Li; Zhi-Min Wei; Yun-Xiao Meng; Xiang-Rui Ji
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

4.  The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target.

Authors:  Kenoki Ohuchida; Kazuhiro Mizumoto; Nami Ishikawa; Kei Fujii; Hiroyuki Konomi; Eishi Nagai; Koji Yamaguchi; Masazumi Tsuneyoshi; Masao Tanaka
Journal:  Clin Cancer Res       Date:  2005-11-01       Impact factor: 12.531

5.  Survival in population-based pancreatic cancer patients: San Francisco Bay area, 1995-1999.

Authors:  Zhihong Gong; Elizabeth A Holly; Paige M Bracci
Journal:  Am J Epidemiol       Date:  2011-11-01       Impact factor: 4.897

6.  Prognostic relevance of altered Fas (CD95)-system in human breast cancer.

Authors:  M Mottolese; S Buglioni; C Bracalenti; M A Cardarelli; L Ciabocco; D Giannarelli; C Botti; P G Natali; A Concetti; F M Venanzi
Journal:  Int J Cancer       Date:  2000-03-20       Impact factor: 7.396

7.  Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape.

Authors:  Wolfram V Bernstorff; Jonathan N Glickman; Robert D Odze; Francis A Farraye; Hong G Joo; Peter S Goedegebuure; Timothy J Eberlein
Journal:  Cancer       Date:  2002-05-15       Impact factor: 6.860

Review 8.  The Fas signalling pathway and its role in the pathogenesis of cancer.

Authors:  Aileen Houston; Joe O'Connell
Journal:  Curr Opin Pharmacol       Date:  2004-08       Impact factor: 5.547

9.  Tissue microarray analysis of Fas and FasL expressions in human non-small cell lung carcinomas; with reference to the p53 and bcl-2 overexpressions.

Authors:  Na-Hye Myong
Journal:  J Korean Med Sci       Date:  2005-10       Impact factor: 2.153

10.  Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma.

Authors:  Wei-Shu Wang; Po-Min Chen; Huann-Sheng Wang; Wen-Yih Liang; Yeu Su
Journal:  Carcinogenesis       Date:  2006-02-10       Impact factor: 4.944

View more
  12 in total

1.  Expression and prognostic value of c-Myc and Fas (CD95/APO1) in patients with pancreatic cancer.

Authors:  Chengzhi He; Hua Jiang; Shasha Geng; Haihui Sheng; Xiaoying Shen; Xiaoyan Zhang; Shizhang Zhu; Ximei Chen; Changqing Yang; Hengjun Gao
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

2.  Association of the expression of unc-51-Like kinase 1 with lymph node metastasis and survival in patients with esophageal squamous cell carcinoma.

Authors:  Lin Jiang; Ben-Song Duan; Jun-Xing Huang; Xia Jiao; Xiao-Wei Zhu; Hai-Hui Sheng; Heng-Jun Gao; Hong Yu
Journal:  Int J Clin Exp Med       Date:  2014-05-15

3.  Cytoplasmic HSP90α expression is associated with perineural invasion in pancreatic cancer.

Authors:  Hua Jiang; Bensong Duan; Chengzhi He; Shasha Geng; Xiaoying Shen; Hongmei Zhu; Haihui Sheng; Changqing Yang; Hengjun Gao
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

4.  UNC51-like kinase 1 as a potential prognostic biomarker for hepatocellular carcinoma.

Authors:  Hongtao Xu; Hong Yu; Xiaoyan Zhang; Xiaoying Shen; Kehao Zhang; Haihui Sheng; Shengbin Dai; Hengjun Gao
Journal:  Int J Clin Exp Pathol       Date:  2013-03-15

5.  SATB1 Promotes Pancreatic Cancer Growth and Invasion Depending on MYC Activation.

Authors:  Zheng Chen; Zengliang Li; Wei Li; Yang Zong; Yi Zhu; Yi Miao; Zekuan Xu
Journal:  Dig Dis Sci       Date:  2015-06-25       Impact factor: 3.199

6.  ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer.

Authors:  Shunrong Ji; Yi Qin; Si Shi; Xiangyuan Liu; Hongli Hu; Hu Zhou; Jing Gao; Bo Zhang; Wenyan Xu; Jiang Liu; Dingkong Liang; Liang Liu; Chen Liu; Jiang Long; Haijun Zhou; Paul J Chiao; Jin Xu; Quanxing Ni; Daming Gao; Xianjun Yu
Journal:  Cell Res       Date:  2015-03-10       Impact factor: 25.617

7.  Silencing c-Myc Enhances the Antitumor Activity of Bufalin by Suppressing the HIF-1α/SDF-1/CXCR4 Pathway in Pancreatic Cancer Cells.

Authors:  Xia Liu; Yayun Zhou; Jiamin Peng; Bei Xie; Qiyang Shou; Jianchao Wang
Journal:  Front Pharmacol       Date:  2020-04-17       Impact factor: 5.810

8.  Calreticulin promotes EGF-induced EMT in pancreatic cancer cells via Integrin/EGFR-ERK/MAPK signaling pathway.

Authors:  Weiwei Sheng; Chuanping Chen; Ming Dong; Guosen Wang; Jianping Zhou; He Song; Yang Li; Jian Zhang; Shuangning Ding
Journal:  Cell Death Dis       Date:  2017-10-26       Impact factor: 8.469

9.  Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640.

Authors:  Clayton S Lewis; Christina Voelkel-Johnson; Charles D Smith
Journal:  Oncotarget       Date:  2016-09-13

10.  Exploring brusatol as a new anti-pancreatic cancer adjuvant: biological evaluation and mechanistic studies.

Authors:  Zheng Lu; Zheng-Quan Lai; Albert W N Leung; Po Sing Leung; Zhao-Shen Li; Zhi-Xiu Lin
Journal:  Oncotarget       Date:  2017-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.